Related Experiment Video
Updated: Jun 25, 2026
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the
M A Pantaleo1, L Landuzzi, G Nicoletti
1Department of Hematology and Oncology Sciences L.A.Seragnoli, Sant'Orsola-Malpighi Hospital, University of Bologna, 40138, Bologna, Italy. maria.pantaleo@unibo.it
Abstract:
The large use of target therapies in the treatment of gastrointestinal stromal tumors (GISTs) highlighted the urgency to integrate new molecular imaging technologies, to develop new criteria for tumor response evaluation and to reach a more comprehensive definition of the molecular target. These aspects, which come from clinical experiences, are not considered enough in preclinical research studies which aim to evaluate the efficacy of new drugs or new combination of drugs with molecular target. We developed a xenograft animal model GIST882 using nude mice. We evaluated both the molecular and functional characterization of the tumor mass. The mutational analysis of KIT receptor of the GIST882 cell lines and tumor mass showed a mutation on exon 13 that was still present after in vivo cell growth. The glucose metabolism and cell proliferation was evaluated with a small animal PET using both FDG and FLT. The experimental development of new therapies for GIST treatment requires sophisticated animal models in order to represent the tumor molecular heterogeneity already demonstrated in the clinical setting and in order to evaluate the efficacy of the treatment also considering the inhibition of tumor metabolism, and not only considering the change in size of tumors. This approach of cancer research on GISTs is crucial and essential for innovative perspectives that could cross over to other types of cancer.
Insights
Developing a new GIST xenograft model in mice allows for better preclinical evaluation of targeted therapies. This model helps assess treatment efficacy by monitoring tumor metabolism and proliferation, not just size.
Area of Science:
- Oncology
- Molecular Biology
- Medical Imaging
Background:
- Targeted therapies are crucial for gastrointestinal stromal tumors (GISTs).
- Preclinical studies need improved models to evaluate new GIST therapies effectively.
- Current preclinical models often lack the molecular heterogeneity seen in clinical GIST cases.
Purpose of the Study:
- To develop and characterize a novel xenograft animal model for GIST research.
- To evaluate the molecular and functional aspects of the GIST xenograft model.
- To establish a preclinical platform for assessing targeted therapy efficacy in GIST.
Main Methods:
- Developed a GIST882 xenograft mouse model.
- Performed mutational analysis of the KIT receptor.
- Utilized small animal Positron Emission Tomography (PET) with FDG and FLT to assess glucose metabolism and proliferation.
Main Results:
- The GIST882 model retained the specific KIT exon 13 mutation after in vivo growth.
- PET imaging demonstrated measurable glucose metabolism and cell proliferation in the xenografts.
- The model reflects key molecular and functional characteristics of human GIST.
Conclusions:
- The GIST882 xenograft model is a valuable tool for preclinical GIST research.
- This model enables comprehensive evaluation of targeted therapies, including metabolic and proliferative effects.
- This approach advances cancer research for GIST and potentially other cancers.
